Outpoll | Outpoll Weekly Recap: Science (March 2

Science

This week in science felt like a page torn from a near-future medical thriller, with prediction markets buzzing over a landmark CRISPR-Cas9 clinical trial that reported preliminary, stunning success in treating a previously incurable genetic cardiomyopathy. The data drop, while still peer-review pending, sent shockwaves through biotech indices and saw contract prices for 'First CRISPR Therapeutic Approval by 2027' surge by over 40% in 48 hours.It's not just about editing genes anymore; it's about editing destinies, and the markets are betting heavily that the regulatory floodgates are about to creak open. Parallel to this, the AI-driven protein folding frontier advanced again, with a new open-source model from a European consortium outperforming its predecessors in predicting complex membrane protein structures—a quiet but monumental leap for rational drug design that had 'AI-Discovered Novel Antibiotic Enters Phase I Trials by Q4 2026' contracts gaining steady traction.Meanwhile, on the climate front, a successful large-scale test of a direct ocean carbon capture system in the Pacific, coupled with a controversial geoengineering paper from MIT, sparked fierce debate and volatile market moves. Contracts on 'Major Government Funding for Marine CDR Announced in 2026' swung wildly, reflecting the high-stakes gamble between technological intervention and ecological precaution.The throughline? Convergence. Biology is no longer just a wet-lab discipline; it's a data science, a climate solution, and an investment thesis all at once, with prediction markets acting as the real-time nervous system measuring the world's confidence in our own ingenuity.

#Weekly recap

Outpoll Weekly Recap: Science (March 2 – 8, 2026)